Logo Logo
Eine Ebene nach oben
Exportieren als [RSS feed] RSS 1.0 [RSS2 feed] RSS 2.0
Gruppiert nach: Dokumententyp | Veröffentlichungsdatum
Springe zu: 2021 | 2020 | 2019 | 2013 | 2012 | 2010 | 2009
Anzahl der Publikationen: 9

2021

Kleer-Reiter, N.; Julmi, S.; Feichtner, F.; Waselau, A.-C.; Klose, C.; Wriggers, P.; Maier, H. J. und Meyer-Lindenberg, Andrea (2021): Biocompatibility and degradation of the open-pored magnesium scaffolds LAE442 and La2. In: Biomedical materials, Bd. 16, Nr. 3, 035037 [PDF, 6MB]

Kleer-Reiter, N.; Julmi, S.; Feichtner, F.; Waselau, A-C; Klose, C.; Wriggers, P.; Maier, H. J. und Meyer-Lindenberg, A. (2021): Biocompatibility and degradation of the open-pored magnesium scaffolds LAE442 and La2. In: Biomedical Materials, Bd. 16, Nr. 3, 35037

2020

Witting, L. M.; Waselau, A.-C.; Feichtner, F.; Wurm, L.; Julmi, S.; Klose, C.; Gartzke, A.-K.; Maier, H. J.; Wriggers, P. und Meyer-Lindenberg, A. (2020): Influence of coatings on degradation and osseointegration of open porous Mg scaffolds in vivo. In: Materialia, Bd. 14, 100949

2019

Kleer, N.; Julmi, S.; Gartzke, A. -K.; Augustin, J.; Feichtner, F.; Waselau, A. -C.; Klose, C.; Maier, H. J.; Wriggers, P. und Meyer-Lindenberg, A. (2019): Comparison of degradation behaviour and osseointegration of the two magnesium scaffolds, LAE442 and La2, in vivo. In: Materialia, Bd. 8, UNSP 100436

2013

Haas, M.; Heinemann, V.; Kullmann, F.; Laubender, Rüdiger P.; Klose, C.; Bruns, C. J.; Holdenrieder, S.; Modest, D. P.; Schulz, C. und Boeck, S. (2013): Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. In: Journal of Cancer Research and Clinical Oncology, Bd. 139, Nr. 4: S. 681-689

2012

Haas, M.; Laubender, Rüdiger P.; Klose, C.; Schulz, C.; Mansmann, Ulrich; Boeck, S. und Heinemann, V. (2012): External Validation of 2 Prognostic Indices for Patients With Advanced Pancreatic Cancer Treated With First-line Therapy. In: Pancreas, Bd. 41, Nr. 5: S. 738-744

2010

Bountogo, M.; Zoungrana, Augustin; Coulibaly, B.; Klose, C.; Mansmann, Ulrich; Mockenhaupt, F. P.; Burhenne, Jürgen; Mikus, Gerd; Walter-Sack, Ingeborg; Schirmer, Heiner; Sie, A.; Meissner, P. und Müller, Olaf (2010): Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso. In: Tropical Medicine and International Health, Bd. 15, Nr. 6: S. 713-717

Boeck, S.; Haas, M.; Laubender, Rüdiger P.; Kullmann, F.; Klose, C.; Bruns, C. J.; Wilkowski, R.; Stieber, P.; Holdenrieder, S.; Buchner, Hannes; Mansmann, Ulrich und Heinemann, V. (2010): Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. In: Clinical Cancer Research, Bd. 16, Nr. 3: S. 986-994

2009

Coulibaly, B.; Zoungrana, Augustin; Mockenhaupt, F. P.; Schirmer, Heiner; Klose, C.; Mansmann, Ulrich; Meissner, P. E. und Müller, Olaf (2009): Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial.
In: PLOS ONE 4(5), e5318 [PDF, 190kB]

Diese Liste wurde am Sat Apr 20 18:51:27 2024 CEST erstellt.